A conbercept dosing regimen of three initial monthly intravitreal injections followed by quarterly treatments appears to be effective in the treatment of neovascular age-related macular degeneration (AMD), yielding visual and anatomic benefits at 3 and 12 months, according to data from the PHOENIX trial.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rivaroxaban may help reduce the incidence of venous thromboembolism (VTE) and VTE-related deaths in patients who are receiving systemic treatment for metastatic malignancies, but only if they keep taking the anticoagulant, according to findings of the phase IIIb CASSINI trial.
A single infusion of tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy, improves overall remission rate (ORR) in children and young adults with CD19+ relapsed/refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL), according to updated results of the ELIANA* study presented at ASH 2018.
MIMS Pharmacist speaks to Cpt. Manvikram Singh Gill, military pharmacist with the Royal Medical and Dental Corps (RMDC) of the Malaysian Armed Forces (MAF),about his work at the Rohingya refugee camp in Cox's Bazar, Bangladesh.
Young, healthy individuals at low risk for atherosclerotic cardiovascular disease (ASCVD) events may still face a heightened lifetime risk of death from CV events if they have elevated LDL-C levels of ≥160 mg/dL, reveal the CCLS*.
The combination of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) more than doubled progression-free survival (PFS) as well as improved overall survival (OS) in patients with CD30-expressing peripheral T-cell lymphoma compared with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), according to results of the phase III ECHELON-2* trial.
The use of the PARP inhibitor olaparib in the maintenance setting confers notable gains in progression-free survival in women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, according to data from the phase III SOLO1 trial.
At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.
Nonsteroidal anti-inflammatory drugs (NSAIDs) appear to increase the risk of major bleeding, stroke or systemic embolism, and hospitalization among patients with atrial fibrillation (AF), suggest the results of the RE-LY* trial. Moreover, there is no difference in the safety and efficacy of dabigatran etexilate (DE) 150 and 110 mg twice daily relative to warfarin.